THE ROLE OF CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER

  • D.M. Almuradova Tashkent Medical Academy, Таshkent, Uzbekistan

Abstract

Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 12-18%  of all BCs.Breast cancer (breast cancer) is the most common oncological disease in women in the Uzbekistan. Data from epidemiological studies show that TNBC is more common in young women (up to 50 years) before menopause. In addition, the likelihood of TNBC is higher in women with early menarche, the first pregnancy at an earlier age, a short period of breastfeeding, and an increased body mass index. It should be not that the prognosis for TNBC does not depend on the degree of differentiation of the tumor, the presence of lymph node metastases, the size of the tumor or the treatment performed. The aggressiveness of TNBC was also confirmed by the maximum risk of recurrence during the first three years after surgical treatment with a maximum mortality within the first 5 years. TNBC is a subtype of tumors with a special character of metastasis. Based on the above, we have undertaken the present work, having set ourselves the following goal: to improve immediate and long-term results of treatment of patients with locally advanced thyroid cancer by using the most effective diagnostic methods and comprehensive treatment.


Keywords: Triple negative BC, neoadjuvant, adjuvant, and metastatic chemotherapy, paclitaxel, docetaxel, gemicitabine

Keywords: Triple negative BC, neoadjuvant, adjuvant, and metastatic chemotherapy, paclitaxel, docetaxel, gemicitabine

Downloads

Download data is not yet available.

References

1. Navruzov SN, Khodzhaev AV, Khudaykulov AT Mammary cancer. Problems of early diagnosis and prevention. Guidelines. - Tashkent, 2013.
2. Petrova GV, Gretsova OP, Starinsky VV and others. Characteristics and methods for calculating statistical indicators used in oncology. - Moscow: FGU MNIOI them. P.A. HerzenRoszdrava, 2011. - 39 p.
3. Khudaykulov AT, Khudaykulov T.K. Socio-economic consequences of mortality of breast cancer in Uzbekistan // Malignant tumors. - 2015. - №1. - P. 53-56.
4. Khudaykulov TK, Khudaykulov AT Epidemiological aspects of breast cancer in Uzbekistan // Bulletin of the Tashkent Medical Academy. - 2013. - №3. - P. 95-97.
5. Ferlay J., Bray F., Pisani P., Parkin D.M.: GLOBOCAN 2008: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No.10 [internet] Lyon, France: IARC; 2010.
6. Ferlay J., Soerjomataram I., Ervik M., et al. (2012). Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. — Available from: http://globocan. iarc.fr, accessed on 11/05/2014.
7. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer in uzbekistan: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 23(Suppl 7):vii11–vii19.
8. NumeridelCancro in Italia. 2014 [The numbers of cancer in Italy. 2014]; Milan: AssociazioneItaliana di OncologiaMedica; 2014. [Accessed July 4, 2015]. Available from: http://www.aiom.it/area+pubblica/area+medica/pubblicazioni/1,332,1. Italian.
9. de Rujters TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res ClinOncol. 2011; 137:183–192. [PMC free article].
10. Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010; 12(Suppl 2):S3. [PMC free article].
11. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16(Suppl 1):S1–S11.
12. Rapoport BL, Nayler S, Demetriou GS, Moodley SD, Benn CA. Triple-negative breast cancer pathologic diagnosis and current chemotherapy treatment options. OncolHematol Rev. 2014; 10(1):25–32.
13. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. ProcNatlAcadSci U S A. 2001; 98(19):10869–10874. [PMC free article].
14. van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(687):530–536.
15. Hortobagyi GN, Hayes D, Pusztai L. Integrating newer science into breast cancer prognosis and treatment: Molecular predictors and profiles. In: Johnson DH, editor. American Society of Clinical Oncology 2002 Annual Meeting Summaries, Orlando, FL, May 18–21 2002. Alexandria, VA: American Society of Clinical Oncology; 2002. pp. 91–202.
16. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J ClinOncol. 2004; 22(12):2284–2293. [PubMed]
17. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429–4434.
18. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750–2767. [PMC free article].
19. Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am SocClinOncolEduc Book. 2015; 35:e31–e39.
20. Tobin NP, Harrell JC, EgyhaziBrage S, et al. Molecular subtype of breast cancer metastases significantly influences patient post-relapse survival. Ann Oncol. 2014; 25(Suppl 1):i5–i7. Abstract.
21. Dent RA, Mainwaring PN, Tan TJY, et al. Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010–2011. J ClinOncol. 2015; 33(Suppl 15):e12075. Abstract.
22. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Breast Cancer version 2.2014. Washington, PA: National Comprehensive Cancer Network; 2014.
23. AssociazioneItaliana di OncologiaMedica (AIOM) LineeGuida: NeoplasiedellaMammella [Guidelines: Neoplasms of the Breast] Milan: AssociazioneItaliana di OncologiaMedica; 2013. Italian.
24. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164–172.
25. Cortazar P, Geyer CE, Jr, Gianni L, Cameron D, von Minckwitz G. Pathological complete response in breast cancer – Authors’ reply. Lancet. 2015; 385:114–115.
26. Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011; 125(1):145–156.
27. Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J ClinOncol. 2012; 30(15):1796–1804.
28. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11(16):5678–5685.
29. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J ClinOncol. 2008; 26(8):1275–1281.
30. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J ClinOncol. 2006; 24(7):1037–1044.
Statistics
31 Views | 78 Downloads
How to Cite
Almuradova, D. (2018). THE ROLE OF CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER. Journal of Drug Delivery and Therapeutics, 8(5), 163-167. https://doi.org/10.22270/jddt.v8i5.1827